RT Journal Article
SR Electronic
T1 Evaluating the impact of COVID-19 on the HIV epidemic among men who have sex with men in Australia: A modelling study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.15.24318054
DO 10.1101/2024.12.15.24318054
A1 Weng, Rongxing
A1 Kwon, Jisoo A.
A1 Hammoud, Mo
A1 Clifton, Brent
A1 Scott, Nick
A1 McGregor, Skye
A1 Gray, Richard T.
YR 2024
UL http://medrxiv.org/content/early/2024/12/16/2024.12.15.24318054.abstract
AB Introduction The initial phase of the coronavirus disease 2019 (COVID-19) pandemic caused significant interruptions to human immunodeficiency virus (HIV) prevention and healthcare services. In Australia, these interruptions coincided with a large reduction in HIV diagnoses but it is unknown if this reflects a reduction in incidence or barriers to testing. We aimed to understand the changes in HIV transmission among men who have sex with men in Australia and the impact of disruptions to HIV prevention, testing and treatment services due to the COVID-19 pandemic and the public health response by incorporating time-sensitive factors in real-world situations.Methods We developed a mathematical model to estimate monthly HIV incidence between January 2020 and August 2022. We obtained aggregated monthly data for sexual partners, condom use, HIV testing, pre-exposure prophylaxis (PrEP) use, and migration. Three scenarios were simulated: 1) a COVID scenario with all changes in place; 2) a no COVID-19 scenario where input parameters remained at pre-COVID-19 values, and 3) a no COVID-19 scenario with continued PrEP scale-up.Results In the absence of the COVID-19 pandemic, the estimated number of cumulative infections from January 2020 to August 2022 would have been 1,266 [95% Percentile Interval (PI): 1,100–1,466] compared to 915 [95% PI: 729–1,181] for the COVID-19 scenario (a 27.7% reduction). The largest reduction in infections (44.3%) occurred in 2020 with 273 (95% PI: 221– 344) infections versus 490 (95% PI: 435–552) in the no-COVID scenario. There was a rebound with 387 infections (95% PI: 307–502) in 2021, followed by a reduction to a stable level by August 2022. Our model identified reductions in sexual partners as the leading factor contributing to the change in HIV infections and diagnoses (−24.8% and −10.5%, respectively).Conclusions A substantial reduction in new HIV infections and diagnoses in Australia occurred during the early stages of the COVID-19 pandemic, which was largely due to reduced HIV transmission. A rebound in infections as sexual partnerships increased between 2021-2022, highlights the imperative to maintain vigorous response efforts and take advantage of the gains made to virtually eliminate HIV transmission in Australia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementRW is supported by an Australian Government Research Training Program Scholarship.The Kirby Institute is funded by the Australian Government Department of Health and is affiliated with the Faculty of Medicine, UNSW Sydney, Australia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study only used publicly available data from Kirby Institute's annual surveillance reports, Kirby Institute's monitoring of PrEP uptake in Australia, the Flux cohort study, and the Gay Community Periodic Survey.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript and Supplementary Materials. The Simple HIV Model code used to produce results for this study along with model input parameters and summary results are available online at https://github.com/The-Kirby-Institute/Simple_HIV_model/